121 related articles for article (PubMed ID: 36525755)
1. Efficacy of chemotherapy in patients with HR+/HER2-Invasive lobular breast cancer.
Yaghi M; Bilani N; Dominguez B; Zerdan MB; Li H; Saravia D; Stone E; Nahleh Z
Cancer Treat Res Commun; 2023; 34():100666. PubMed ID: 36525755
[TBL] [Abstract][Full Text] [Related]
2. Management of HR+/HER2+ lobular breast cancer and trends do not mirror better outcomes.
Yaghi M; Bilani N; Dominguez B; Jabbal IS; Rivera C; Bou Zerdan M; Li H; Saravia D; Stone E; Nahleh Z
Breast; 2022 Aug; 64():112-120. PubMed ID: 35640346
[TBL] [Abstract][Full Text] [Related]
3. Adjuvant chemotherapy could not bring survival benefit to HR-positive, HER2-negative, pT1b-c/N0-1/M0 invasive lobular carcinoma of the breast: a propensity score matching study based on SEER database.
Hu G; Hu G; Zhang C; Lin X; Shan M; Yu Y; Lu Y; Niu R; Ye H; Wang C; Xu C
BMC Cancer; 2020 Feb; 20(1):136. PubMed ID: 32085753
[TBL] [Abstract][Full Text] [Related]
4. Relative effectiveness of adjuvant chemotherapy for invasive lobular compared with invasive ductal carcinoma of the breast.
Marmor S; Hui JYC; Huang JL; Kizy S; Beckwith H; Blaes AH; Rueth NM; Tuttle TM
Cancer; 2017 Aug; 123(16):3015-3021. PubMed ID: 28382636
[TBL] [Abstract][Full Text] [Related]
5. Adjuvant chemotherapy in patients with invasive lobular carcinoma and use of the 21-gene recurrence score: A National Cancer Database analysis.
Weiser R; Polychronopoulou E; Hatch SS; Haque W; Ghani HA; He J; Kuo YF; Gradishar WJ; Klimberg VS
Cancer; 2022 May; 128(9):1738-1747. PubMed ID: 35137951
[TBL] [Abstract][Full Text] [Related]
6. The effect of (neo)adjuvant chemotherapy on long-term survival outcomes in patients with invasive lobular breast cancer treated with endocrine therapy: A retrospective cohort study.
Öztekin S; Hooning MJ; van Deurzen CHM; Dietvorst AHP; Drooger JC; Kitzen JJEM; Martens JWM; van der Padt-Pruijsten A; Vastbinder MB; Zuetenhorst H; Heemskerk-Gerritsen BAM; Jager A
Cancer; 2024 Mar; 130(6):927-935. PubMed ID: 37985357
[TBL] [Abstract][Full Text] [Related]
7. The prognosis of invasive ductal carcinoma, lobular carcinoma and mixed ductal and lobular carcinoma according to molecular subtypes of the breast.
Zhao H
Breast Cancer; 2021 Jan; 28(1):187-195. PubMed ID: 32812198
[TBL] [Abstract][Full Text] [Related]
8. Adjuvant chemotherapy in lobular carcinoma of the breast: a clinicopathological score identifies high-risk patient with survival benefit.
de Nonneville A; Jauffret C; Gonçalves A; Classe JM; Cohen M; Reyal F; Mazouni C; Chauvet MP; Chopin N; Colombo PE; Jouve E; Darai E; Rouzier R; Coutant C; Gimbergues P; Azuar AS; de Lara CT; Lambaudie E; Houvenaeghel G
Breast Cancer Res Treat; 2019 Jun; 175(2):379-387. PubMed ID: 30759288
[TBL] [Abstract][Full Text] [Related]
9. Factors Associated With the Decision to Decline Chemotherapy in Patients With Early-stage, ER+/HER2- Breast Cancer and High-risk Scoring on Genomic Assays.
Bilani N; El Ladki S; Yaghi M; Main O; Jabbal IS; Elson L; Bou Zerdan M; Liang H; Nahleh Z
Clin Breast Cancer; 2022 Jun; 22(4):367-373. PubMed ID: 35190262
[TBL] [Abstract][Full Text] [Related]
10. Neoadjuvant Endocrine Therapy Versus Neoadjuvant Chemotherapy in Node-Positive Invasive Lobular Carcinoma.
Thornton MJ; Williamson HV; Westbrook KE; Greenup RA; Plichta JK; Rosenberger LH; Gupta AM; Hyslop T; Hwang ES; Fayanju OM
Ann Surg Oncol; 2019 Oct; 26(10):3166-3177. PubMed ID: 31342392
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of Single-Agent Chemotherapy for Patients with Advanced Invasive Lobular Carcinoma: A Pooled Analysis from Three Clinical Trials.
Pérez-Garcia J; Cortés J; Metzger Filho O
Oncologist; 2019 Aug; 24(8):1041-1047. PubMed ID: 30578311
[TBL] [Abstract][Full Text] [Related]
12. Outcomes in Premenopausal Patients with HR+/HER2- Breast Cancer and Lymph Node Micrometastasis Based on the 21-Gene Recurrence Score.
Bilani N; Patel R; Crowley F; Tiersten A
Oncologist; 2023 Dec; 28(12):1049-1054. PubMed ID: 37682780
[TBL] [Abstract][Full Text] [Related]
13. Mixed Invasive Ductal and Lobular Carcinoma of the Breast: Prognosis and the Importance of Histologic Grade.
Metzger-Filho O; Ferreira AR; Jeselsohn R; Barry WT; Dillon DA; Brock JE; Vaz-Luis I; Hughes ME; Winer EP; Lin NU
Oncologist; 2019 Jul; 24(7):e441-e449. PubMed ID: 30518616
[TBL] [Abstract][Full Text] [Related]
14. Estimating the overall survival benefit of adjuvant chemo-endocrine therapy in women over age 50 with pT1-2N0 early stage breast cancer and 21-gene recurrence score ≥26: A National Cancer Database analysis.
Stabellini N; Cao L; Towe CW; Amin AL; Montero AJ
Cancer Med; 2023 Oct; 12(19):19607-19616. PubMed ID: 37766666
[TBL] [Abstract][Full Text] [Related]
15. Magnitude of trastuzumab benefit in patients with HER2-positive, invasive lobular breast carcinoma: results from the HERA trial.
Metzger-Filho O; Procter M; de Azambuja E; Leyland-Jones B; Gelber RD; Dowsett M; Loi S; Saini KS; Cameron D; Untch M; Smith I; Gianni L; Baselga J; Jackisch C; Bell R; Sotiriou C; Viale G; Piccart-Gebhart M
J Clin Oncol; 2013 Jun; 31(16):1954-60. PubMed ID: 23589556
[TBL] [Abstract][Full Text] [Related]
16. Does the 21-gene recurrence score have clinical utility in HR+/HER2+ breast cancer?
Bilani N; Crowley F; Mohanna M; Itani M; Yaghi M; Saravia D; Jabbal I; Dominguez B; Liang H; Nahleh Z
Breast; 2022 Dec; 66():49-53. PubMed ID: 36137495
[TBL] [Abstract][Full Text] [Related]
17. Outcomes of pleomorphic lobular carcinoma versus invasive lobular carcinoma.
Haque W; Arms A; Verma V; Hatch S; Brian Butler E; Teh BS
Breast; 2019 Feb; 43():67-73. PubMed ID: 30496936
[TBL] [Abstract][Full Text] [Related]
18. Secondary Invasive Breast Events among Patients with Hormone-Positive Breast Cancer and High-Risk Oncotype DX Recurrence Scores 26-30 and ≥31.
Berger NF; Zimmerman BS; Tharakan S; Suchman K; Cascetta KP; Blanter J; Moshier E; Ru M; Jaffer S; Tiersten A
Oncology; 2021; 99(11):699-702. PubMed ID: 34425579
[TBL] [Abstract][Full Text] [Related]
19. HER-2 low status in early-stage invasive lobular carcinoma of the breast: associated factors and outcomes in an institutional series.
Rothschild HT; Clelland E; Patterson A; Molina-Vega J; Kaur M; Symmans WF; Schwartz CJ; Chien AJ; Mukhtar RA
Breast Cancer Res Treat; 2023 Jun; 199(2):349-354. PubMed ID: 37017812
[TBL] [Abstract][Full Text] [Related]
20. Impact of 21-Gene Expression Assay on Clinical Outcomes in Node-Negative ≤ T1b Breast Cancer.
Pomponio M; Keele L; Hilt E; Burkbauer L; Goldbach M; Nazarian S; Fox K; Tchou J
Ann Surg Oncol; 2020 May; 27(5):1671-1678. PubMed ID: 31686348
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
